Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

類似資料

• Overall survival benefit with pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA, a randomised Phase 3 study
  著者:: Swain, Sandra M., 等
  出版事項: (2013)
• Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
  著者:: Baselga, José, 等
  出版事項: (2011)
• Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
  著者:: Swain, Sandra M., 等
  出版事項: (2013)
• Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
  著者:: Miles, David, 等
  出版事項: (2013)
• Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
  著者:: Swain, S. M., 等
  出版事項: (2014)